EB Wound Burden
Severe EB can involve chronic wound burden, pain, infection risk, and complex day-to-day care needs.
Development Program
CAV-121 for Epidermolysis Bullosa
CAV-121 is an investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa. The program is informed by antimicrobial peptide-inspired science and the need for new approaches to severe EB wound burden.
CAV-121 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established.
Program Snapshot
CAV-121
- Candidate
- CAV-121
- Focus
- Epidermolysis Bullosa
- Modality
- Ceragenin-based therapeutic candidate
- Scientific Basis
- Cathelicidin-inspired innate immune biology
- Status
- Investigational product candidate
Innate Immune Biology
The scientific rationale connects skin and wound biology with antimicrobial peptide-inspired mechanisms.
Investigational Program
CAV-121 is described as an investigational therapeutic candidate; no approval, safety, or efficacy claims are made.
Development Capabilities
Cross-functional support for the CAV-121 program
The development team includes expertise across regulatory strategy, CMC, clinical development, formulation, translational science, bioinformatics, and program management.
Meet the development teamDevelopment / Program Lead
Regulatory
CMC
Bioinformatics / PM
Clinical Operations / PM
Drug Product Formulation
Finance / Business Development
Clinical
Regulatory Note
CAV-121 is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established. Information on this website is provided for company and scientific communication purposes and is not medical advice.